Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioAtla, Inc.BCAB · Entity 879 | Director | June 18, 2025 | June 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioAtla, Inc.
Report date June 18, 2025 · Filed June 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,125 |
Reported balance
After 2025-06-18 transaction · row 1
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 23,500 · Balance 59,125 F1: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2025 Filed Jun 18, 2025 19:43 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantCommon Stock | 23,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-088061 · ownership.xml · nonDerivative · entry 1 MCBRINN SYLVIA · CIK 0001284666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,125 F1 · shares: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 16:16 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantCommon Stock | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073681 · ownership.xml · nonDerivative · entry 1 MCBRINN SYLVIA · CIK 0001284666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,625 F1 · shares: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 13, 2025, and (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date. Read SEC document |
| December 26, 2023 Filed Dec 26, 2023 19:43 UTC | BioAtla, Inc. BCAB · Entity 879 | PurchaseCommon Stock | 4,000 | $2.33 | $9,320.00 |
DisclosureSEC source: 0001209191-23-059720 · doc4.xml · nonDerivative · entry 1 MCBRINN SYLVIA · CIK 0001284666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,125 F1 · price: The range of prices for the shares of Common Stock is from $2.325 to $2.33. The Reporting Person undertakes that she will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| September 08, 2023 Filed Sep 13, 2023 18:55 UTC | BioAtla, Inc. BCAB · Entity 879 | PurchaseCommon Stock | 2,000 | $2.54 | $5,080.00 |
DisclosureSEC source: 0001209191-23-049347 · doc4.xml · nonDerivative · entry 1 MCBRINN SYLVIA · CIK 0001284666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,125 Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 18:38 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001209191-23-037545 · doc4.xml · derivative · entry 1 MCBRINN SYLVIA · CIK 0001284666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 14, 2024 or (b) the day before the next annual meeting of stockholders, subject to the reporting person continuing to provide services through the vesting date. Read SEC document |
| March 28, 2023 Filed Jan 19, 2024 16:21 UTC | BioAtla, Inc. BCAB · Entity 879 | PurchaseCommon Stock | 4,000 | $2.35 | $9,400.00 |
DisclosureSEC source: 0001209191-24-001929 · doc4.xml · nonDerivative · entry 1 MCBRINN SYLVIA · CIK 0001284666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,125 Read SEC document |
| December 19, 2022 Filed Dec 19, 2022 17:41 UTC | BioAtla, Inc. BCAB · Entity 879 | PurchaseCommon Stock | 3,700 | $8.33 | $30,813.23 |
DisclosureSEC source: 0001209191-22-062000 · doc4.xml · nonDerivative · entry 1 MCBRINN SYLVIA · CIK 0001284666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,125 Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 17:28 UTC | BioAtla, Inc. BCAB · Entity 879 | PurchaseCommon Stock | 2,000 | $8.27 | $16,539.60 |
DisclosureSEC source: 0001209191-22-058723 · doc4.xml · nonDerivative · entry 1 MCBRINN SYLVIA · CIK 0001284666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,425 Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 18:09 UTC | BioAtla, Inc. BCAB · Entity 879 | PurchaseCommon Stock | 1,000 | $8.20 | $8,200.00 |
DisclosureSEC source: 0001209191-22-050147 · doc4.xml · nonDerivative · entry 2 MCBRINN SYLVIA · CIK 0001284666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| September 12, 2022 Filed Sep 15, 2022 18:09 UTC | BioAtla, Inc. BCAB · Entity 879 | PurchaseCommon Stock | 2,000 | $8.85 | $17,700.00 |
DisclosureSEC source: 0001209191-22-050147 · doc4.xml · nonDerivative · entry 1 MCBRINN SYLVIA · CIK 0001284666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 19:58 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (right to buy) · Derivative | 5,695 | $0.00 Strike: $39.64 | $0.00 |
DisclosureSEC source: 0001209191-22-038185 · doc4.xml · derivative · entry 2 MCBRINN SYLVIA · CIK 0001284666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,615 Underlying: Common Stock · 5,695 shares Expires 2031-06-15 F2 · security: On June 17, 2021, the reporting person filed a Form 4 in respect of an option covering 24,615 shares. Such option was granted on June 15, 2021 pursuant to the Company's non-employee director compensation policy. The Company subsequently determined that 5,695 of the shares comprising such award were null and void upon grant as a result of the $750,000 annual limit for non-employee director compensation under its 2020 Equity Incentive Plan. As a result on June 16, 2022, the Board of the Company granted a make-whole option covering 5,695 shares to the reporting person. Such make-whole option has the same vesting, expiration and other terms as the option granted on June 15, 2021. F3 · derivative.exercise_date: 1/3 of the total number of shares subject to the make-whole option were fully vested and exercisable on the date of the grant and 1/36th of the total number of shares subject to the make-whole option shall vest monthly commencing on July 15, 2022, subject to the reporting person continuing to provide services to the Company throughout the vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 19:58 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-22-038185 · doc4.xml · derivative · entry 1 MCBRINN SYLVIA · CIK 0001284666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 16, 2023 or (b) the next annual meeting of stockholders, subject to the reporting person continuing to provide services through the vesting date. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 17:29 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (right to buy) · Derivative | 24,615 | $0.00 Strike: $39.64 | $0.00 |
DisclosureSEC source: 0001209191-21-041574 · doc4.xml · derivative · entry 1 MCBRINN SYLVIA · CIK 0001284666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,615 Underlying: Common Stock · 24,615 shares Expires 2031-06-15 F1 · derivative.exercise_date: 1/3 of the total number of shares subject to the Option shall vest and become exercisable on the earlier of (a) June 15, 2022 or (b) the next annual meeting of stockholders, and 1/36th of the total number of shares shall vest monthly thereafter, subject to the Optionee continuing to provide services to the Company through the vesting date. Read SEC document |
| June 15, 2021 Filed Jun 17, 2022 19:56 UTC Amendment | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (right to buy) · Derivative | 18,920 | $0.00 Strike: $39.64 | $0.00 |
DisclosureSEC source: 0001209191-22-038182 · doc4a.xml · derivative · entry 1 MCBRINN SYLVIA · CIK 0001284666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,920 Underlying: Common Stock · 18,920 shares Expires 2031-06-15 F1 · shares: On June 17, 2021, the reporting person filed a Form 4 in respect of an option covering 24,615 shares. Such option was granted on June 15, 2021 pursuant to the Company's non-employee director compensation policy. The Company subsequently determined that 5,695 of the shares comprising such award were null and void upon grant as a result of the $750,000 annual limit for non-employee director compensation under its 2020 Equity Incentive Plan. F2 · derivative.exercise_date: 1/3 of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 15, 2022 or (b) the next annual meeting of stockholders, and 1/36th of the total number of shares shall vest monthly thereafter, subject to the reporting person continuing to provide services to the Company through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.